Cellcentric Ltd.
Clinical trials sponsored by Cellcentric Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for blood cancer patients: experimental drug CCS1477 enters human trials Results expected Mar 2027 (estimated)
-
Can a new triple therapy outsmart resistant myeloma?
Disease control Recruiting nowThis phase 3 trial is testing whether adding an experimental drug called inobrodib to a standard two-drug regimen (pomalidomide and dexamethasone) can help people whose multiple myeloma has come back or stopped responding to prior treatments. Participants will be randomly assigne…
Phase 3 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for hard-to-treat myeloma: experimental combo targets relapsed patients
Disease control Recruiting nowThis study tests a new drug, inobrodib, combined with two standard medicines (pomalidomide and dexamethasone) in 100 adults whose multiple myeloma has come back or no longer responds to available therapies. The goal is to see how well the combination shrinks tumors and to learn m…
Phase 2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for blood cancer patients: experimental drug CCS1477 enters human trials
Disease control Recruiting nowThis study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…
Phase 1/2 • Sponsor: CellCentric Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC